SCHEMBL3372610

SCHEMBL3372610

COc1cc(-c2nc(N)c(C#N)c(-c3ccc(Cl)cc3Cl)n2)cc(OC)c1OC

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3A P49840 1/20 0.55
GSK3B P49841 1/20 0.55
DYRK1A Q13627 1/20 0.55
CLK4 Q9HAZ1 1/20 0.55
DPP4 P27487 12/20 0.52
ADORA2A P29274 1/20 0.47
ADORA1 P30542 1/20 0.47
KDM4E B2RXH2 4/20 0.46
HSD17B10 Q99714 3/20 0.46
MAPK1 P28482 1/20 0.46
ALDH1A1 P00352 3/20 0.46
NPSR1 Q6W5P4 2/20 0.46
MAPT P10636 2/20 0.46
USP2 O75604 2/20 0.46
HPGD P15428 2/20 0.46
LMNA P02545 1/20 0.46
POLB P06746 1/20 0.46
CYP3A4 P08684 1/20 0.43
CNR1 P21554 1/20 0.43
CNR2 P34972 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3372051 0.82 DPP4 (0.70) GSK3AGSK3BDYRK1ACLK4DPP4
SCHEMBL3369334 0.82 DPP4 (0.77) DPP4CYP3A4
SCHEMBL6871446 0.81 DPP4 (0.66) GSK3AGSK3BDYRK1ACLK4DPP4
SCHEMBL3372730 0.81 DPP4 (0.65) GSK3AGSK3BDYRK1ACLK4DPP4
SCHEMBL3368098 0.78 DPP4 (0.68) GSK3AGSK3BDYRK1ACLK4DPP4
SCHEMBL6871445 0.76 DPP4 (0.67) GSK3AGSK3BDYRK1ACLK4DPP4
SCHEMBL3372212 0.72 DPP4 (0.78) DPP4CYP3A4
SCHEMBL3369971 0.70 DPP4 (0.75) DPP4CYP3A4
SCHEMBL6221315 0.69 DPP4 (0.73) GSK3AGSK3BDYRK1ACLK4DPP4
SCHEMBL7501358 0.68 MEN1 (0.70) ADORA2AADORA1KDM4EALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1476435-B1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-06-30 EP disclosed
US-7022718-B2 Pyridine and pyrimidine derivatives HOFFMANN-LA ROCHE INC. (US) 2006-04-04 US disclosed
US-20050143405-A1 Pyridine and pyrimidine derivatives BOEHRINGER MARKUS (CH) 2005-06-30 US disclosed
US-6867205-B2 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. (US) 2005-03-15 US disclosed
EP-1476435-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2004-11-17 EP disclosed
WO-2003068757-A9 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES HOFFMANN LA ROCHE (CH) 2004-10-07 WO disclosed
US-20030216382-A1 Pyridine and pyrimidine derivatives HOFFMAN-LA ROCHE INC. 2003-11-20 US disclosed
WO-2003068757-A1 NOVEL PYRIDIN- AND PYRIMIDIN-DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2003-08-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030216382-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, G6PC1 GSK3A 2021/4885GSK3B 1969/4885DYRK1A 2008/4885
US-20050143405-A1 Pyridine and pyrimidine derivatives DPP4, GPR119, PDXK GSK3A 2252/4885GSK3B 2013/4885DYRK1A 1141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.